Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) has expanded its Pure Bliss™ by Similac® line of infant formulas to include organic and European-made products. The new offerings include:
- Pure Bliss Organic: USDA-certified organic formula available in powder and liquid forms
- Pure Bliss Organic with A2 Milk: USDA-certified organic formula using milk from select cows producing A2 beta-casein protein
- Pure Bliss Irish Farms: Made in Ireland with fresh milk from Irish cows
Notably, Pure Bliss Organic in 2-fluid ounce ready-to-feed bottles is the only USDA-certified organic liquid infant formula available in select U.S. retail stores. These products aim to meet diverse parental preferences for infant nutrition, offering options that are organic, European-made, and easy to digest. The expanded line is available at Amazon, Target, and Walmart.
Abbott Fund's scholarship program at the University of the Pacific is training future healthcare workers to combat diabetes in their communities. The program offers master's degrees for nurses and social workers with specialization in diabetes management, as well as certificate programs for frontline workers. Graduates like Harry Ma, Alex Marapao, and Ana Garcia are now making a difference in their hometown of Stockton, California.
The program aims to strengthen the pipeline of homegrown healthcare workers and address the growing costs of diabetes, which reached $412.9 billion in the U.S. in 2022. Scholars commit to working in the local healthcare system for at least two years after graduation, applying their specialized knowledge to improve patient care and outcomes.
Abbott has partnered with local organizations in Stockton, Calif. since 2019 to fight diabetes through a community-led management program. The initiative includes health screenings for over 1,400 residents, a 'food as medicine' program lowering HbA1c levels, and free transportation to medical appointments. Scholarships from the Abbott Fund support local healthcare students specializing in diabetes. Results indicate significant improvements in residents' health, with the program showing a decrease in HbA1c levels by 0.8% on average. The initiative demonstrates the power of community collaboration in addressing chronic diseases.
Abbott (NYSE: ABT) has announced a global partnership with Medtronic to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. This collaboration aims to improve health outcomes and reduce the burden of decision-making for people with diabetes who use intensive insulin therapy.
The partnership involves developing a CGM sensor based on Abbott's advanced Libre technology, designed exclusively for Medtronic devices. This integration will enable automatic adjustments of insulin to maintain glucose levels within the desired range. The new CGM sensor will be developed by Abbott but sold by Medtronic.
This alliance marks Abbott's fourth partnership with major insulin delivery system developers, expanding choices for people worldwide to benefit from Libre technology connectivity. The collaboration targets the estimated 11 million people globally who require multiple daily insulin injections, including those with Type 1 and Type 2 diabetes.
Cadrenal Therapeutics (Nasdaq: CVKD) has initiated discussions with Abbott (NYSE: ABT) regarding a planned pivotal study of tecarfarin in patients with recently implanted Left Ventricular Assist Devices (LVADs). Tecarfarin, a late-stage anticoagulant, received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in patients with implanted mechanical circulatory support devices. The collaboration focuses on improving anticoagulation treatment for HeartMate 3™ LVAD patients, currently the only LVAD available in the United States.
A recent analysis of the ARIES-HM3 study by Abbott highlighted that high-quality anticoagulation can further enhance outcomes with the HeartMate 3 LVAD. Prior clinical studies suggest that tecarfarin may provide improved anticoagulation quality, particularly in patients on multiple medications or with impaired renal function, both common in LVAD patients.
Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have launched the second year of their Innovation Incubator initiative to improve access to nutritious food and health in underserved communities. Eight community health centers across the U.S. will receive $30,000 each, along with expert guidance and training, to develop and test innovative solutions for integrating healthy food into clinical care.
The initiative aims to address food insecurity, which affects 12.8% of U.S. households, and its impact on chronic conditions like obesity, diabetes, and heart disease. Selected health centers will work on projects ranging from creating community gardens to providing customized nutrition for expectant mothers and people with chronic diseases. The results will be shared with 1,400 health centers nationwide, potentially benefiting over 31 million patients.
Real Madrid, the 2023-2024 UEFA Champions League, Spanish Super Cup, and La Liga winners, will embark on their 23rd U.S. summer tour as part of the Soccer Champions Tour 2024. The tour includes three matches against top clubs:
1. July 31: Real Madrid vs. AC Milan at Soldier Field, Chicago
2. August 3: Real Madrid vs. FC Barcelona at MetLife Stadium, New Jersey
3. August 6: Real Madrid vs. Chelsea FC at Bank of America Stadium, Charlotte
As Health Sciences and Nutrition Partner of Real Madrid and Global Partner of the Real Madrid Foundation, Abbott is collaborating with the club to support children worldwide through nutrition education and science-based innovation. Their joint initiative, "Beat Malnutrition," aims to raise awareness and reduce malnutrition globally.
Abbott and its nonprofit partners are focusing on disaster resilience in communities most impacted by natural disasters. Since 2006, Abbott has partnered with Feeding America and Direct Relief to prepare for hurricane season by providing:
1. 'Disaster Relief Packs' to food banks, containing nutrition products for 12,000 people this year.
2. 'Disaster Relief Modules' to 80 health clinics, serving over 2,000 people.
Abbott is now expanding beyond preparedness to build year-round resilience through targeted strategies in New Orleans, Dallas, Orlando, and Puerto Rico. This includes grants for infrastructure and systems at food banks and community health clinics. Over the past decade, Abbott and the Abbott Fund have provided more than $50 million in funding and products for disaster relief efforts worldwide.
Abbott (NYSE: ABT) reported strong financial results for Q2 2024, with total sales of $10.4 billion, marking a 4.0% reported sales growth and 9.3% organic growth, driven by a double-digit rise in Medical Devices sales. GAAP diluted EPS was $0.74, while adjusted EPS reached $1.14. Abbott raised its full-year 2024 EPS guidance to $3.30-$3.40 on a GAAP basis and $4.61-$4.71 adjusted. The company also anticipates 9.5%-10.0% organic sales growth, excluding COVID-19 testing sales.
Key approvals include the FDA's nod for the Esprit™ BTK system and two new over-the-counter continuous glucose monitoring systems. Additionally, Abbott received CE Mark for the AVEIR® dual chamber leadless pacemaker system. Global Medical Devices sales surged by 10.2%, with notable growth in Diabetes Care and Electrophysiology segments. Abbott's robust R&D pipeline contributed significantly, with 10 new growth opportunities announced in the first half of 2024.
Abbott (NYSE: ABT) is set to release its second-quarter 2024 financial results on Thursday, July 18, before the market opens.
The company will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), which will be accessible on Abbott's Investor Relations website.
An archived edition of the call will also be available later the same day.